Molteni Farmaceutici and the FarmaMondo Group signed an exclusive marketing and distribution agreement for certain Molteni’s products of its pain and addiction management portfolio in
Amryt Pharma and the FarmaMondo Group signed an exclusive partnership agreement for the orphan disease innovative therapies Myalept®, Lojuxta® in the APAC region.
FarmaMondo and Accendatech USA Inc. partnered to initiate a Managed Access Program for the compassionate supply of ACT-001 for patients in Hong Kong. Under the
FarmaMondo participates in the Arab Health conference in Dubai from 24-27 January 2022. After a break of 2 years, FarmaMondo is delighted to be physically
We use cookies that are strictly necessary to operate this website.
We also use optional cookies to improve your accessibility to our website and its functionality, to analyse and track your use of our website and to give you the best possible user experience.
You will need to activate optional cookies. For more detailed information on our use of cookies on this website, please read our Cookie Policy, which also explains how to customise your Cookies settings.
You can also accept all our cookies or customise your Cookies settings by clicking on the buttons provided below.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.